8-K: Theriva Biologics Reports Q3 2025 Results, VCN-01 Progress

Theriva Biologics announced its third quarter 2025 financial results and provided updates on its oncology pipeline, including positive VCN-01 data and an extended cash runway.

Summary

• Net loss for the third quarter ended September 30, 2025, was $(4.361) million, an improvement from $(7.726) million for the same period in 2024.
• Cash and cash equivalents totaled $7.5 million as of September 30, 2025, which increased to $15.5 million as of November 10, 2025, following recent capital raises.
• The company's current cash position is expected to fund operations into the first quarter of 2027.
• Expanded data from the VIRAGE Phase 2b trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC) were presented at ESMO 2025, showing improved overall survival (OS), progression-free survival (PFS), and Duration of Response (DoR) when VCN-01 was combined with standard-of-care chemotherapy.
• Preclinical data for VCN-12, a next-generation oncolytic virus, were presented at the ESGCT 32nd Annual Congress, demonstrating increased cell killing and hyaluronidase activity compared to VCN-01, and a persistent anti-tumor immune response in animal studies.
• General and administrative expenses decreased by 18% to $1.9 million for Q3 2025, primarily due to lower compensation costs and a workforce reduction implemented on September 30, 2025.
• Research and development expenses decreased by 7% to $2.6 million for Q3 2025, mainly due to the completion of the VIRAGE Phase 2b clinical trial and lower expenses for the SYN-004 trial.

Sentiment

Score: 7

Explanation: The company reported a reduced net loss and extended its cash runway, which are positive financial indicators. More importantly, the successful completion of a Phase 2b trial for its lead candidate VCN-01 with positive expanded data, and promising preclinical data for VCN-12, represent significant scientific and clinical progress. While future funding is needed for pivotal trials, the current position allows for regulatory discussions and continued development.

Positives

• Net loss significantly decreased to $(4.361) million in Q3 2025 from $(7.726) million in Q3 2024.
• Successful completion of the VIRAGE Phase 2b clinical trial for VCN-01 in metastatic PDAC.
• Expanded VCN-01 data presented at ESMO 2025 showed improved overall survival, progression-free survival, and duration of response in metastatic PDAC patients.
• VCN-01 demonstrated persistent bioactivity upon repeated dosing despite the presence of neutralizing antibodies.
• Positive preclinical data for the next-generation oncolytic virus VCN-12, showing increased cell killing and anti-tumor immune response.
• Cash and cash equivalents increased to $15.5 million as of November 10, 2025, extending the cash runway into Q1 2027.
• General and administrative expenses decreased by 18% due to workforce reduction and lower compensation costs.
• Research and development expenses decreased by 7% due to trial completions.

Negatives

• The company continues to operate at a net loss of $(4.361) million for Q3 2025 and $(21.743) million for the nine months ended September 30, 2025.
• Additional funding will be required to initiate new VCN-01 clinical trials beyond the current cash runway.
• Accrued expenses significantly increased from $3.368 million at December 31, 2024, to $7.685 million at September 30, 2025.
• Non-current contingent consideration increased from $6.973 million at December 31, 2024, to $10.793 million at September 30, 2025.
• In-process research and development impairment of $1.325 million was recorded for the nine months ended September 30, 2025.
• Goodwill impairment of $1.526 million was recorded for the nine months ended September 30, 2025.

Risks

• Product candidates, including VCN-01 and VCN-12, may not demonstrate safety and effectiveness in clinical indications or produce results consistent with prior findings.
• The ability to confirm VCN-12 preclinical data in a clinical setting is uncertain.
• The company may not reach clinical milestones, enroll the expected number of patients, or complete clinical trials on time to achieve desired results and benefits.
• There is no guarantee of obtaining regulatory approval for commercialization of product candidates or complying with ongoing regulatory requirements.
• Regulatory limitations may restrict the company's ability to promote or commercialize its product candidates for specific indications.
• Acceptance of product candidates in the marketplace and the successful development, marketing, or sale of the company's products are not assured.
• Developments by competitors could render the company's products obsolete or non-competitive.
• The company's ability to maintain license agreements and the continued maintenance and growth of its patent estate are critical.
• The company's ability to remain well-financed is crucial, and additional funding will be required to initiate new VCN-01 clinical trials.
• Other factors described in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and its other SEC filings could materially affect actual results.

Future Outlook

The company plans to discuss a protocol for a proposed Phase 3 study of VCN-01 in metastatic PDAC with the European Medicines Agency and the US FDA. They are also designing a potential Phase 2/3 clinical trial for retinoblastoma, with discussions with regulators anticipated in the first half of 2026. General and administrative and research and development expenses are expected to decrease due to a workforce reduction and the completion of the VIRAGE trial. Current cash is projected to fund operations into Q1 2027, but additional funding will be required to initiate new VCN-01 clinical trials.

Management Comments

• "Recent presentations of clinical data for VCN-01 and preclinical data for VCN-12 at medical congresses have highlighted the progress made across our oncology pipeline." Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
• "Having successfully completed the VIRAGE Phase 2b clinical trial, we are now pursuing interactions with the European Medicines Agency and the US FDA to seek alignment on a protocol for a proposed Phase 3 study of VCN-01 plus gemcitabine/nab-paclitaxel standard-of-care chemotherapy as first-line treatment for metastatic PDAC." Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
• "In addition, we have made significant progress on the design of a potential Phase 2/3 clinical trial in the rare pediatric disease retinoblastoma for potential discussion with regulators in the first half of 2026." Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
• "With capital raised from our recent warrant inducement and sales made pursuant to our at-the-market (ATM) facility, we are well positioned to advance our regulatory and clinical strategies and explore potential partnerships for the innovative assets in our pipeline." Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.

Industry Context

The company is advancing its oncology pipeline with oncolytic viruses, a growing area in cancer therapy. VCN-01 targets metastatic pancreatic ductal adenocarcinoma (PDAC), a disease with high unmet need and poor prognosis, where new treatment options are highly sought after. The development of VCN-12, a next-generation oncolytic virus, indicates a commitment to innovation within the gene and cell therapy space, aiming to improve upon existing candidates by enhancing stroma degradation and tumor cell lysis. The focus on regulatory interactions for Phase 3 trials aligns with typical biopharmaceutical development pathways for bringing novel therapies to market.

Comparison to Industry Standards

• The VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC, showing improved OS, PFS, and DoR, positions VCN-01 as a promising candidate in a challenging cancer indication. Standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) for metastatic PDAC typically yields median overall survival rates of 8-12 months, so any significant improvement is notable.
• The preclinical data for VCN-12, demonstrating increased cell killing and hyaluronidase activity compared to VCN-01, suggests potential for a more potent oncolytic virus, which is a common goal in the development of next-generation therapies in the gene and cell therapy sector.
• The company's cash runway into Q1 2027, following recent capital raises, provides a reasonable timeframe for a clinical-stage biotech to advance regulatory discussions and preclinical work, though it is typical for such companies to require additional funding for pivotal trials.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from reduced net loss, extended cash runway, and positive clinical/preclinical data for pipeline assets. Potential dilution from future capital raises.
• Employees: Negative impact from workforce reduction implemented on September 30, 2025.
• Patients (PDAC): Potential future benefit from VCN-01 if Phase 3 trials are successful and lead to approval.
• Patients (Retinoblastoma): Potential future benefit from VCN-01 if Phase 2/3 trials are successful.
• Creditors: Improved financial stability due to extended cash runway.

Next Steps

• Discuss a study protocol for a potential Phase 3 clinical trial of VCN-01 in metastatic PDAC with regulators in Europe and the United States.
• Continue progress on the design of a potential Phase 2/3 clinical trial in retinoblastoma for discussion with regulators in the first half of 2026.
• Conduct additional preclinical studies to confirm VCN-12 findings.
• Continue exploratory VCN-01 manufacturing scale-up activities.
• Continue supporting other preclinical and discovery initiatives.
• Seek additional funding to initiate new VCN-01 clinical trials.

Key Dates

Recommendation

The company has demonstrated significant clinical progress with VCN-01, showing improved outcomes in a challenging indication like metastatic PDAC, and has promising preclinical data for VCN-12. The extension of the cash runway into Q1 2027 provides crucial time for regulatory discussions and further development. However, the company remains unprofitable, and substantial additional funding will be required to initiate pivotal Phase 3 trials, which carries inherent dilution risk. While the clinical data is encouraging, the stock is a "hold" until there is more clarity on the path to commercialization, successful regulatory alignment for Phase 3, and a clearer funding strategy for these expensive later-stage trials. The workforce reduction, while improving G&A, also signals ongoing cost management challenges.

Keywords

Theriva Biologics, TOVX, VCN-01, VCN-12, pancreatic cancer, PDAC, oncolytic virus, oncology, clinical trial, Phase 2b, Phase 3, retinoblastoma, financial results, Q3 2025, cash runway, biopharmaceutical, drug development, ESMO, ESGCT